Discoveries of genetic mutations which confer resistance to cardiovascular diseases, including the discovery of protective mutations in the ANGPTL3 gene
Prior to joining Verve in July 2019, he served as director of the Massachusetts General Hospital Center for Genomic Medicine and was the Ofer and Shelly Nemirovsky MGH Research Scholar. He also served as director of the Cardiovascular Disease Initiative at the Broad Institute and was a Professor of Medicine at Harvard Medical School.
In 2023, Verve established a global collaboration with Eli Lilly for advancing programs in cardiovascular disease,[4] and the pharmaceutical giant announced a $1.3 billion deal to buy Verve in 2025 as they sought to expand their experimental medicines pipeline [5] by targeting the three lipoprotein drivers of atherosclerosis: low-density lipoproteins, triglyceride-rich lipoproteins, and lipoprotein(a).
Education
He received his M.D. from Harvard Medical School in 1997. He then completed his clinical training in internal medicine and cardiology at Massachusetts General Hospital, where he served as chief resident in Internal Medicine from 2002 to 2003. Kathiresan pursued postdoctoral research training from 2003 to 2008 in cardiovascular genetics through a combined experience at the Broad Institute and the Framingham Heart Study, jointly mentored by Drs. David Altshuler, Joel Hirschhorn, and Christopher J. O'Donnell. In 2008, he joined the faculty of the Massachusetts General Hospital Cardiology Division, Cardiovascular Research Center, and Center for Genomic Medicine.
Kathiresan has helped highlight new biological mechanisms underlying heart attack, discovered mutations that protect against heart attack risk, highlighted triglyceride-rich lipoproteins as a therapeutic target, and developed a framework to interpret the genome for heart attack risk which includes monogenic, somatic, and polygenic drivers of disease risk.[6] His work has also challenged the assumption that high levels of HDL cholesterol, often referred to as "good cholesterol," are protective against heart attacks.[3] His clinical focus is the prevention of myocardial infarction in individuals with a family history of heart attack.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
